These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8669848)

  • 61. A review of the use of somatostatin analogs in oncology.
    Keskin O; Yalcin S
    Onco Targets Ther; 2013; 6():471-83. PubMed ID: 23667314
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Peptide receptor targeting in cancer: the somatostatin paradigm.
    Barbieri F; Bajetto A; Pattarozzi A; Gatti M; Würth R; Thellung S; Corsaro A; Villa V; Nizzari M; Florio T
    Int J Pept; 2013; 2013():926295. PubMed ID: 23476673
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival.
    Li D; Tanaka M; Brunicardi FC; Fisher WE; Gibbs RA; Gingras MC
    Cancer; 2011 Jul; 117(13):2863-72. PubMed ID: 21692047
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.
    Rodon J; DeSantos V; Ferry RJ; Kurzrock R
    Mol Cancer Ther; 2008 Sep; 7(9):2575-88. PubMed ID: 18790742
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.
    O'Byrne KJ; Dobbs N; Propper DJ; Braybrooke JP; Koukourakis MI; Mitchell K; Woodhull J; Talbot DC; Schally AV; Harris AL
    Br J Cancer; 1999 Mar; 79(9-10):1413-8. PubMed ID: 10188884
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Human somatostatin receptor mediated antiproliferative action evokes subtype selective cytotoxic and cytostatic signaling.
    Srikant CB
    Yale J Biol Med; 1997; 70(5-6):541-8. PubMed ID: 9825481
    [No Abstract]   [Full Text] [Related]  

  • 67. The role of somatostatin analogs in the management of medullary thyroid carcinoma.
    Lupoli GA; Fonderico F; Fittipaldi MR; Colarusso S; Panico A; Cavallo A; Di Micco L; Lupoli G
    J Endocrinol Invest; 2003; 26(8 Suppl):72-4. PubMed ID: 15233217
    [No Abstract]   [Full Text] [Related]  

  • 68. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
    J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.
    Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN
    Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
    Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
    Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
    Bontenbal M; Foekens JA; Lamberts SW; de Jong FH; van Putten WL; Braun HJ; Burghouts JT; van der Linden GH; Klijn JG
    Br J Cancer; 1998; 77(1):115-22. PubMed ID: 9459155
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
    Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
    Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels.
    Canobbio L; Cannata D; Miglietta L; Boccardo F
    Anticancer Res; 1995; 15(6B):2687-90. PubMed ID: 8669848
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues.
    Pollak M
    Digestion; 1996; 57 Suppl 1():29-33. PubMed ID: 8813463
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.